Trials / Completed
CompletedNCT05577624
A Study to Evaluate the Drug-drug Interaction Effect of Rifampin on the Pharmacokinetics of AMG 510 in Healthy Participants
An Open-label Study to Evaluate the Drug-drug Interaction Effect of Rifampin, a CYP3A4 Inducer, on the Pharmacokinetics of AMG 510 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of AMG 510 alone and in combination with rifampin in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 510 | Oral tablet |
| DRUG | Rifampin | Oral capsule |
Timeline
- Start date
- 2019-11-05
- Primary completion
- 2019-12-01
- Completion
- 2019-12-01
- First posted
- 2022-10-13
- Last updated
- 2025-03-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05577624. Inclusion in this directory is not an endorsement.